Twin Health CAIHL draft report

Twin Health: CAIHL reassessment

September 8, 2026. Published AI-assisted draft.

Twin Health combines sensor-based guidance and clinical care with employer and health-plan contracts. Patient authority when personal goals differ from program cost or medication-reduction goals remains unclear. Current policy documents correction rights and a separate clinical-data notice.

Scope and agency posture

AI digital-twin metabolic care program with a clinical team and employer/plan contracts, not a standalone patient chatbot.

Posture: Mixed, potentially agency-expanding.

Axis: 58/100, retained provisionally. No numerical recalibration was performed.

Sources and documented findings

• The current US site describes sensor-driven daily guidance and clinical care, and prominently markets GLP-1 elimination and reduced sponsor costs. These are documented program objectives, not proof of unwanted medication withdrawal. https://usa.twinhealth.com/

• The current privacy policy permits deidentified data for a generative lifestyle tool, allows information correction and profile-deletion requests with exceptions, distinguishes device-manufacturer obligations, and directs member health information to the medical group's separate notice. https://usa.twinhealth.com/legal/privacy

Patient authority

Inference from the documented workflow: Members receive individualized guidance, but the public pages do not establish how they can retain a preferred treatment goal when it differs from program cost or medication-reduction targets.

Critical capacity

Editorial assessment: Personal data and daily feedback can support reflection. Clinical outcome studies do not establish the ability to inspect a model recommendation or negotiate its objective.

Informed control

Editorial assessment: The current policy adds concrete correction rights and a separate clinical-data scope. It does not support a blanket claim that all identifiable health data is shared with employers.

Assessment and limits

Mixed remains grounded in actual program objectives and conditional control. Record the disclosed deidentified reuse without equating it with identified-data sale.

Confidence: Moderate for program and policy statements.

Remaining uncertainty: Individual sponsor reporting, clinical notice details, recommendation explanations and care-plan negotiation remain unverified

Published documentation is evidence of stated conditions, not proof of actual implementation. Unknowns did not receive automatic negative points. Funding, sponsorship, and public code do not determine agency by themselves.

Review provenance

• Reviewer/model: OpenAI Codex / GPT-6.
• Method: Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
• Human review: Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
• Earlier review: 2026-06-12. Historical assessment. Earlier claims are not automatically reverified by this publication.